Apparently horrible trial results for currently promoted drugs combined with Mirapex going off patent and losing Flomax to generic as well has led to a cut of 600 or more reps in the USA.
Notifications were on Tuesday morning via a phone call to impacted reps.
8 comments:
Its a massacre at BI. Huge cuts!
While the CEOs of this company collect bonus checks to well exceed what they are paid in salary. This system in America is wrong.......the people at the top or board of directors take from the cookie jar. They are even guaranteed payments if the company doesn't make a profit.
The Sales rep for these companies have always been a grunt for these people.
DMs are on the chopping block today, RDs tommorrow. Same thing - by phone.
actually closer to 1800 laid off
Is it just sales?
Anything to do with the poor results so-far for Dabigitran?
Numerous internal positions will be moved to the Germany headquarters. Internal people will find out soon enough.
BI sales will be highly dependent on the new "Clinical Science Consultants," whom are medically degree people (MD, PharmD, PA, RN, etc.), based upon the thought that practicing physicians will prescribe more because of the degree association.
Wrong move.
"Clinical Science Consultants" is just a fancy term for off-label promotion. I know. I used to be one.
Post a Comment